A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children With Juvenile Myelomonocytic Leukemia (JMML)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Melphalan (Primary) ; Busulfan; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
Indications Graft-versus-host disease; Juvenile myelomonocytic leukaemia
Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use

07 May 2018 Status changed from active, no longer recruiting to completed.
28 Nov 2016 Status changed from suspended to active, no longer recruiting.
20 Jan 2016 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com